Quoin Pharmaceuticals, Ltd. financial data

Symbol
QNRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
23 Hata'as Street, Kfar Saba, Israel
State of incorporation
Israel
Former names
Cellect Biotechnology Ltd. (to 10/15/2021), Cellect Biomed Ltd. (to 7/7/2016)
Latest financial report
10-Q - Q3 2024 - Nov 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 330 % -9.1%
Debt-to-equity 93.9 % +9.41%
Return On Equity -126 % -26.5%
Return On Assets -64.8 % -21.3%

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 5.05M shares
Entity Public Float 5.8M USD +53.6%
Common Stock, Value, Issued 0 USD

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.36M USD +8.94%
Nonoperating Income (Expense) 640K USD -10.3%
Net Income (Loss) Attributable to Parent -8.7M USD -0.73%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.12M USD -1.48%
Assets, Current 10.5M USD -25.8%
Intangible Assets, Net (Excluding Goodwill) 508K USD -18.9%
Assets 11.4M USD -24.4%
Accounts Payable, Current 223K USD -7.23%
Accrued Liabilities, Current 1.5M USD -42%
Liabilities, Current 3.47M USD -24.2%
Other Liabilities, Noncurrent 2.47M USD -19.5%
Liabilities 5.95M USD -22.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -52.9M USD -220%
Retained Earnings (Accumulated Deficit) -52.9M USD -19.7%
Stockholders' Equity Attributable to Parent 5.44M USD -26.6%
Liabilities and Equity 11.4M USD -24.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.43M USD +17.9%
Net Cash Provided by (Used in) Financing Activities 5.33M USD -7.25%
Net Cash Provided by (Used in) Investing Activities -4.47M USD -27.9%
Common Stock, Shares Authorized 100M shares +1100%
Common Stock, Shares, Issued 5.05M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.12M USD -1.48%
Deferred Tax Assets, Valuation Allowance 6.22M USD +41.5%
Deferred Tax Assets, Gross 6.22M USD +41.5%
Deferred Tax Assets, Operating Loss Carryforwards 4.28M USD +28.3%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 58.3M USD +6.97%
Amortization of Intangible Assets 101K USD -3.22%
Share-based Payment Arrangement, Expense 1.23M USD +16.4%